These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 25444904)
1. Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement. Won YS; Jeong JS; Kim SJ; Ju MH; Lee SW Cancer Lett; 2015 Jan; 356(2 Pt B):918-28. PubMed ID: 25444904 [TBL] [Abstract][Full Text] [Related]
2. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo. Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model. Jeong JS; Lee SW; Hong SH; Lee YJ; Jung HI; Cho KS; Seo HH; Lee SJ; Park S; Song MS; Kim CM; Kim IH Clin Cancer Res; 2008 Jan; 14(1):281-90. PubMed ID: 18172280 [TBL] [Abstract][Full Text] [Related]
4. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme. Song MS; Jeong JS; Cho KS; Lee SW Exp Mol Med; 2007 Dec; 39(6):722-32. PubMed ID: 18160843 [TBL] [Abstract][Full Text] [Related]
5. Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through MicroRNA Regulation. Kim J; Won R; Ban G; Ju MH; Cho KS; Young Han S; Jeong JS; Lee SW Sci Rep; 2015 Jul; 5():12315. PubMed ID: 26189916 [TBL] [Abstract][Full Text] [Related]
6. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. Hong SH; Jeong JS; Lee YJ; Jung HI; Cho KS; Kim CM; Kwon BS; Sullenger BA; Lee SW; Kim IH Mol Ther; 2008 Jan; 16(1):74-80. PubMed ID: 17700543 [TBL] [Abstract][Full Text] [Related]
7. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript. Kwon BS; Jung HS; Song MS; Cho KS; Kim SC; Kimm K; Jeong JS; Kim IH; Lee SW Mol Ther; 2005 Nov; 12(5):824-34. PubMed ID: 16040278 [TBL] [Abstract][Full Text] [Related]
8. Use of tumor-targeting trans-splicing ribozyme for cancer treatment. Lee SW; Jeong JS Methods Mol Biol; 2014; 1103():83-95. PubMed ID: 24318888 [TBL] [Abstract][Full Text] [Related]
9. Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme. Song MS; Lee SW FEBS Lett; 2006 Sep; 580(21):5033-43. PubMed ID: 16949075 [TBL] [Abstract][Full Text] [Related]
10. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Gu J; Kagawa S; Takakura M; Kyo S; Inoue M; Roth JA; Fang B Cancer Res; 2000 Oct; 60(19):5359-64. PubMed ID: 11034071 [TBL] [Abstract][Full Text] [Related]
11. In vivo reprogramming of human telomerase reverse transcriptase (hTERT) by trans-splicing ribozyme to target tumor cells. Lee SJ; Lee SW; Jeong JS; Kim IH Methods Mol Biol; 2010; 629():307-21. PubMed ID: 20387158 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096 [TBL] [Abstract][Full Text] [Related]
13. Selective and efficient retardation of cancers expressing cytoskeleton-associated protein 2 by targeted RNA replacement. Ban G; Jeong JS; Kim A; Kim SJ; Han SY; Kim IH; Lee SW Int J Cancer; 2011 Aug; 129(4):1018-29. PubMed ID: 21328343 [TBL] [Abstract][Full Text] [Related]
14. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. Zhang PH; Zou L; Tu ZG J Surg Res; 2006 Mar; 131(1):143-9. PubMed ID: 16298398 [TBL] [Abstract][Full Text] [Related]
15. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy. Murofushi Y; Nagano S; Kamizono J; Takahashi T; Fujiwara H; Komiya S; Matsuishi T; Kosai K Int J Oncol; 2006 Sep; 29(3):681-8. PubMed ID: 16865285 [TBL] [Abstract][Full Text] [Related]
16. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells. Hayashidani Y; Hiyama E; Murakami Y; Sueda T Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061 [TBL] [Abstract][Full Text] [Related]
17. Liver-specific gene therapy of hepatocellular carcinoma by targeting human telomerase reverse transcriptase with pegylated immuno-lipopolyplexes. Hu Y; Shen Y; Ji B; Yin S; Ren X; Chen T; Ma Y; Zhang Z; Zhang Y Eur J Pharm Biopharm; 2011 Aug; 78(3):320-5. PubMed ID: 21220007 [TBL] [Abstract][Full Text] [Related]
18. Intracellular efficacy of tumor-targeting group I intron-based trans-splicing ribozyme. Kwon BS; Jeong JS; Won YS; Lee CH; Yoon KS; Hyung Jung M; Kim IH; Lee SW J Gene Med; 2011 Feb; 13(2):89-100. PubMed ID: 21322101 [TBL] [Abstract][Full Text] [Related]
19. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Komata T; Kondo Y; Kanzawa T; Hirohata S; Koga S; Sumiyoshi H; Srinivasula SM; Barna BP; Germano IM; Takakura M; Inoue M; Alnemri ES; Shay JW; Kyo S; Kondo S Cancer Res; 2001 Aug; 61(15):5796-802. PubMed ID: 11479218 [TBL] [Abstract][Full Text] [Related]
20. [Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference]. Zhang PH; Tu ZG; Yang MQ; Huang WF; Zou L; Zhou YL Ai Zheng; 2004 Jun; 23(6):619-25. PubMed ID: 15191658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]